Antivirals (SARS-CoV-2)
- Used to prevent progression in high-risk disease
- Nirmatrelvir/ritonavir: preferred oral option
- Remdesivir: IV alternative
- Start early in symptomatic infection
- Ritonavir causes major CYP3A interactions
- Renal/hepatic function affects eligibility
- Antibiotics do not treat uncomplicated COVID
Class at a glance
- Used to prevent progression in high-risk disease
Members / distinctions
- Remdesivir: IV alternative
Clinical role
- Nirmatrelvir/ritonavir: preferred oral option
- Ritonavir causes major CYP3A interactions
- Antibiotics do not treat uncomplicated COVID
Other clinical roles
- Start early in symptomatic infection
- Renal/hepatic function affects eligibility
Self-check
- Which enzyme pathway drives ritonavir interactions?
CYP3A. - Which IV alternative treats SARS-CoV-2 infection?
Remdesivir.
Drugs in this class (4)
All drug classes · Open Antivirals (SARS-CoV-2) in the interactive console ↗